Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$195.45 USD

195.45
3,453,379

-1.37 (-0.70%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Home Depot, AbbVie, Broadcom, 3M and Morgan Stanley

The Zacks Analyst Blog Highlights: Home Depot, AbbVie, Broadcom, 3M and Morgan Stanley

Easy Investing Secrets to an Early Retirement - August 13, 2020

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

AbbVie Outperforms Large-Cap Pharma Industry Year to Date

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.

Sheraz Mian headshot

Top Analyst Reports for Home Depot, AbbVie & Broadcom

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot (HD), AbbVie (ABBV) and Broadcom (AVGO).

Kinjel Shah headshot

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.

Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts

Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.

Signs That Your Trading Will Ruin Your Retirement - August 11, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y

Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - August 10, 2020

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus

Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.

Ironwood (IRWD) Q2 Earnings Beat on Solid Linzess Sales

Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. COVID-19 impacts enrollment in clinical studies.

Want To Retire Early? Learn the Intelligent Investing Secret - August 05, 2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Benjamin Rains headshot

3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio

Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...

Signs That Your Trading Will Ruin Your Retirement - August 03, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

ImmunoGen (IMGN) Q2 Earnings and Sales Beat, Shares Down

ImmunoGen (IMGN) reports encouraging second-quarter results. Top-line data from pivotal study on its lead candidate, mirvetuximab soravtansine, likely to be delayed by six to eight weeks.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - August 03, 2020

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

AbbVie's (ABBV) Q2 Earnings and Revenues Beat Estimates

AbbVie (ABBV) beats on second-quarter 2020 earnings and revenues. Shares up in pre-market trading.

Mark Vickery headshot

More Earnings, Data Following Big Tech Q2 Blowout: XOM, MRK, CAT & More

Markets finish out a busy week in the heart of Q2 earnings season with plenty of other leaders across a spectrum of industries, plus a few new economic reports.

Earnings & Economic Data Deluge

Earnings & Economic Data Deluge

AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 4.46% and 2.99%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for AbbVie (ABBV)

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Amgen (AMGN) Stock Moves Lower Despite Q2 Earnings Beat

Amgen (AMGN) beats Q2 estimates for both earnings and sales. It maintains its previously-issued sales guidance while raising the earnings range. Stock dips.

Why the Earnings Surprise Streak Could Continue for AbbVie (ABBV)

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.